PARP1-Driven Apoptosis in Chronic Lymphocytic Leukemia

Table 2

PCR and immunoblotting results.

	All patients	15 patients (pretreatment)	15 patients (posttreatment)	𝑃^∗
PARP1-mRNA, median (range)^1	0.094 (0.001–3.490)	0.088 (0.001–3.490)	0.055 (0.003–0.535)	0.507
116 kDa fragment, median (range)^2	0.532 (0–1.808)	0.528 (0.263–0.673)	0.551 (0.311–0.864)	0.308
89 kDa fragment, median (range)^2	0.665 (0.202–2.097)	0.647 (0.202–1.002)	0.607 (0.162–0.992)	0.875
116/89 ratio, median (range)†	1.182 (0.754–1.589)	1.245 (0.754–1.589)	1.095 (0.444–1.554)	0.026
	All patients	Healthy donors
PARP1-mRNA, median (range)^1	0.094 (0.001–3.490)	0.24 (0.024–1.762)		0.364

1PARP1/ACTB ratio; ²PARP1/ACTB expression ratio.
*Correlation between pre- and posttreatment levels was performed using the related samples Wilcoxon Signed Rank test.
†Four (4/26) patients did not have a measurable 116 kDa molecule. One of them was in the 15-patient group that was given treatment. Following treatment, 3/15 patients did not have a measurable 116 kDa molecule. For these patients the calculation of 116/89 ratio was not performed, and they were excluded from the relevant statistical analysis.